Levi & Korsinsky notifies investors that it has commenced an investigation into Akebia Therapeutics, Inc. (NASDAQ: AKBA) concerning potential violations of the federal securities laws.
On October 29, 2025, Akebia announced that it will not pursue the VALOR trial for Vafseo label expansion in non-dialysis chronic kidney disease patients due to FDA Type C meeting feedback requiring a significantly larger patient population, increasing time and costs. Following this news, AKBA’s stock price fell over 31% to open at $2.12 per share.
If you suffered a loss on your Akebia Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





